Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 5:28 pm Unchanged | 2021-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | Vivo Ventures VI LLC | 1,383,179 5.700% | 0 (Unchanged) | Filing History |
| 2022-02-11 5:23 pm Sale | 2021-12-31 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Vivo Ventures VI LLC | 139 13.000% | -55,431 (-99.75%) | Filing History |
| 2022-02-11 5:20 pm Unchanged | 2021-12-31 | 13G | Verona Pharma plc VRNA | Vivo Ventures VI LLC | 23,493,716 4.900% | 0 (Unchanged) | Filing History |
| 2021-08-06 4:30 pm Sale | 2021-08-05 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Vivo Ventures VI LLC | 55,570 4.910% | -4,000 (-6.71%) | Filing History |
| 2021-02-12 4:30 pm Unchanged | 2020-12-31 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Vivo Ventures VI LLC | 59,570 5.500% | 0 (Unchanged) | Filing History |
| 2021-02-12 4:30 pm Purchase | 2020-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | Vivo Ventures VI LLC | 1,383,179 5.900% | 360,686 (+35.28%) | Filing History |
| 2020-07-24 4:30 pm Purchase | 2020-07-22 | 13G | Verona Pharma plc VRNA | Vivo Ventures VI LLC | 23,493,716 5.700% | 12,444,448 (+112.63%) | Filing History |
| 2020-02-13 4:30 pm Purchase | 2019-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV | Vivo Ventures VI LLC | 1,022,493 5.700% | 97,412 (+10.53%) | Filing History |